Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab/relatlimab - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Nivolumab/relatlimab - Bristol-Myers Squibb

Alternative Names: BMS-936558/BMS-986016; BMS-986213; Nivolumab and relatlimab-rmbw - Bristol-Myers Squibb; Nivolumab/relatlimab-rmbw - Bristol Myers Squibb; Opdualag; Relatlimab-rmbw/nivolumab - Bristol Myers Squibb; Relatlimab/nivolumab - Bristol Myers Squibb

Latest Information Update: 23 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Phase II Squamous cell cancer
  • Phase I/II Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 07 Oct 2024 Phase-III clinical trials in Non-small cell lung cancer (Recurrent, Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in USA (unspecified route) (NCT06561386)
  • 26 Sep 2024 Launched for Malignant melanoma (In adults, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In children, In the elderly, First-line therapy, In adolescents) in Canada (IV)
  • 23 Aug 2024 Bristol-Myers Squibb plans a phase III RELATIVITY1093 trial for Non-small Cell Lung Cancer (Combination therapy, Recurrent, Late-stage disease, First-line therapy) in USA, Argentina, Australia, Austria, Belgium, Brazil, Chile, China, Denmark, France, Germany, India, Italy, Japan, South Korea, Netherlands, Poland, Romania, Spain, Switzerland, Taiwan, and the United Kingdom in September 2024 (NCT06561386)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top